Study of the Pan-ERBB Inhibitor Neratinib Given in Combination With Everolimus, Palbociclib or Trametinib in Advanced Cancer Subjects With EGFR Mutation/Amplification, HER2 Mutation/Amplification or HER3/4 Mutation
Conditions: Malignant Neoplasm of Breast; Malignant Neoplasms of Digestive Organs; Malignant Neoplasms of Female Genital Organs; Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites; Malignant Neoplasms of Independent (Primary) Multiple Sites; Malignant Neoplasms of Lip Oral Cavity and Pharynx; Malignant Neoplasms of Mesothelial and Soft Tissue; Malignant Neoplasms of Respiratory and Intrathoracic Organs; Malignant Neoplasms of Thyroid and Other Endocrine Glands; Malignant Neoplasms of Urinary Tract; Neoplasms of Uncertain or Unknown Beh avior Interventions: Drug: Neratinib; Drug: Everolimus; Drug: Palbociclib; Drug: Trametinib Sponsors: M.D. Anderson Cancer Center; Pfizer; Puma Biotechnology, Inc. Not yet recruiting - verified February 2017
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Biotechnology | Cancer | Cancer & Oncology | HER2 | Oral Cancer | Oral Cavity Cancer | Pfizer | Pharyngeal Cancer | Respiratory Medicine | Study | Thyroid | Thyroid Cancer